½ÃÀ庸°í¼­
»óǰÄÚµå
1595115

°ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀå : ÇØºÎÇÐ, ¾à¹° À¯Çü, Åõ¿© °æ·Î, ±¸¸Å ÆÐÅÏ, À¯Åë ä³Îº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Osteoarthritis Therapeutics Market by Anatomy, Drug Type, Route of Administration, Purchasing Pattern, Distribution Channel - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 196 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

°ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀåÀº 2023³â¿¡ 79¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 86¾ï 9,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 10.39%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 157¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

°ñ°üÀý¿° Ä¡·áÁ¦´Â ¿¬°ñ ÆÄ±«¸¦ Ư¡À¸·Î ÇÏ´Â ÅðÇ༺ °üÀý ÁúȯÀÎ °ñ°üÀý¿°ÀÇ Áõ»óÀ» ¿ÏÈ­Çϰí ÁøÇàÀ» ´ÊÃß±â À§ÇÑ ´Ù¾çÇÑ Ä¡·á¹ýÀ» ¸»Çϸç, ºñ½ºÅ×·ÎÀ̵强 ¼Ò¿°ÁøÅëÁ¦(NSAIDs), ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å, ÁøÅëÁ¦, »ý¹°ÇÐÀû Á¦Á¦, À¯ÀüÀÚ ¹× Áٱ⼼Æ÷ Ä¡·á¿Í °°Àº »õ·Î¿î Ä¡·á¹ýÀ» Æ÷ÇÔÇÏÁö¸¸ ÀÌ¿¡ ±¹ÇѵÇÁö´Â ¾Ê½À´Ï´Ù. µîÀÌ Æ÷ÇÔµÇÁö¸¸, ÀÌ¿¡ ±¹ÇѵÇÁö´Â ¾Ê½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·áÁ¦ÀÇ Çʿ伺Àº °í·ÉÈ­, ºñ¸¸À² Áõ°¡, »ýȰ½À°ü º¯È­ µîÀ¸·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î °ñ°üÀý¿°ÀÇ À¯º´·üÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·áÁ¦´Â ÅëÁõ°ú ¿°ÁõÀ» ÁÙÀÌ°í °üÀý ±â´ÉÀ» °³¼±Çϱâ À§ÇÑ °ÍÀ¸·Î, ÁַΠŬ¸®´Ð, º´¿ø ¹× ÀçÅÃÄ¡·á¿¡¼­ »ç¿ëµÇ´Â ȯÀÚµéÀ» ´ë»óÀ¸·Î ÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀº ±â¼ú ¹ßÀü, R&D ÅõÀÚ Áõ°¡, Á¶±â ÀçȰ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º´¿ë¿ä¹ý ¹× ÃÖ¼Òħ½ÀÀû ½Ã¼úÀÇ °³¹ßÀº Å« ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ±â¾÷µéÀº Çõ½ÅÀûÀÎ ±â¼ú¿¡ ÅõÀÚÇϰí Àü·«Àû Á¦ÈÞ ¹× Àμö¸¦ ÅëÇØ Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇÔÀ¸·Î½á ÀÚº»À» È®ÃæÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº Ä¡·á ºñ¿ë, ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç, ÀáÀçÀûÀÎ ºÎÀÛ¿ëÀº ½ÃÀå È®´ë¿¡ Á¦¾àÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. Çõ½Å°ú ¿¬±¸´Â ºñ¿ë È¿À²ÀûÀ̰í, ȯÀÚ Ä£È­ÀûÀ̸ç, ºÎÀÛ¿ëÀÌ ÀûÀº Ç¥Àû Ä¡·á¹ý °³¹ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾î¾ß ÇÕ´Ï´Ù. AI¿Í ¸Ó½Å·¯´×À» Ȱ¿ëÇÏ¿© ȯÀÚ °³°³ÀÎÇÁ·ÎÆÄÀÏ¿¡ ¸Â´Â ¸ÂÃãÇü ÀǷḦ °³¹ßÇÏ´Â °ÍÀº °æÀï ¿ìÀ§¸¦ °¡Á®´Ù ÁÙ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå ȯ°æÀº ¿ªµ¿ÀûÀ̸ç, ºü¸¥ ¹ßÀü°ú ²÷ÀÓ¾ø´Â ÀûÀÀÀÌ ÇÊ¿äÇÑ °æÀï ȯ°æÀ¸·Î Ư¡Áö¾îÁý´Ï´Ù. Áúº´ÀÇ ¸ÞÄ¿´ÏÁòÀ» ÀÌÇØÇϰí Àü´Þ ½Ã½ºÅÛÀ» °³¼±Çϱâ À§ÇØ °íµµÀÇ ¿¬±¸¿¡ ÅõÀÚÇÏ´Â ±â¾÷Àº ¼º°øÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. À¯¸ÁÇÑ ½ÃÀåÀÌÁö¸¸, ±ÔÁ¦ ¹®Á¦¸¦ ±Øº¹ÇÏ°í ´õ ¸¹Àº ȯÀÚÃþ¿¡ µµ´ÞÇÒ ¼ö ÀÖ´Â ÀûÁ¤ °¡°ÝÀ» È®º¸ÇØ¾ß Çϸç, °ñ°üÀý¿° °ü¸®¿¡ ´ëÇÑ Æø³ÐÀº Á¢±Ù°ú ±³À°À» ÃËÁøÇϱâ À§ÇØ Á¤ºÎ ¹× ÀÇ·á ±â°ü°úÀÇ Çù·ÂÀÇ Çʿ伺ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023) 79¾ï ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 86¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 157¾ï 8,000¸¸ ´Þ·¯
CAGR(%) 10.39%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â °ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

°ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ¿ÏÈ­Çϰí, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Àü ¼¼°èÀûÀ¸·Î Áõ°¡ÇÏ´Â °ñ°üÀý¿°ÀÇ À¯º´·ü
    • ÃÖ¼Òħ½À¼ö¼ú¿¡ ´ëÇÑ ÀáÀçÀû ¼ö¿ä
    • Àü ¼¼°è ½ºÆ÷Ã÷ ºÎ»ó Áõ°¡¿Í ÇÔ²² Áõ°¡ÇÏ´Â ³ëÀÎ Àα¸ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • NSAIDÀÇ ºÎÀÛ¿ë¿¡ ´ëÇÑ ¿ì·Á
  • ½ÃÀå ±âȸ
    • °ñ°üÀý¿°¿¡ ´ëÇÑ »õ·Î¿î ÀǾàǰ Ä¡·á¹ý
    • °ñ°üÀý¿° ºÐ¾ß¿¡¼­ÀÇ Áö¼ÓÀûÀÎ ¿¬±¸ °³¹ß
    • °ñ°üÀý¿° Ä¡·á¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø È®´ë
    • ½ÅÈï±¹ÀÇ 1Àδç ÀÇ·áºñ Áõ°¡
  • ½ÃÀå °úÁ¦
    • ºñ¾à¹°Àû ÅëÁõ °ü¸® ¿ä¹ýÀÇ ±Þ¼ÓÇÑ È®»ê

Portre's Five Forces: °ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀå Ž»öÀ» À§ÇÑ Àü·«Àû µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : °ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ·Â ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº °ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® °ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

°ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º °ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â °ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

°ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

°ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTLE ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå °ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀå : ÇØºÎÇк°

  • ¼Õ °ñ°üÀý¿°
  • ÅðÇ༺ °í°üÀýÁõ
  • ÅðÇ༺ ½½°üÀýÁõ
  • ¼Ò°üÀý °ñ°üÀý¿°

Á¦7Àå °ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ À¯Çüº°

  • ÁøÅëÁ¦
    • Acetaminophen
    • Duloxetine
  • ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å
  • ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦
    • Aspirin
    • Diclofenac
    • Ibuprofen
    • Naproxen
  • °üÀý³» º¸Ãæ ¿ä¹ýÁ¦

Á¦8Àå °ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀå : Åõ¿© °æ·Îº°

  • °æ±¸ Åõ¿©
  • ºñ°æ±¸ Åõ¿©
  • ±¹¼Ò

Á¦9Àå °ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀå : ±¸ÀÔ ÆÐÅϺ°

  • ½ÃÆÇ¾à
  • 󹿾à

Á¦10Àå °ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀå : À¯Åë ä³Îº°

  • º´¿ø ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹
  • ¼Ò¸Å ¾à±¹

Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ °ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦13Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °ñ°üÀý¿° Ä¡·áÁ¦ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • Almatica Pharma LLC
  • Anika Therapeutics, Inc.
  • Assertio Therapeutics, Inc.
  • Atnahs Pharma UK Limited
  • Bayer AG
  • Bioventus
  • Eli Lilly and Company
  • Ferring B.V.
  • Fidia Farmaceutici s.p.a.
  • Flexion Therapeutics, Inc.
  • GlaxoSmithKline PLC
  • Hanmi Pharm. Co., Ltd.
  • Horizon Therapeutics PLC
  • Kitov Pharmaceuticals Ltd.
LSH

The Osteoarthritis Therapeutics Market was valued at USD 7.90 billion in 2023, expected to reach USD 8.69 billion in 2024, and is projected to grow at a CAGR of 10.39%, to USD 15.78 billion by 2030.

Osteoarthritis therapeutics refer to a wide array of treatments designed to alleviate the symptoms and slow the progression of osteoarthritis, a degenerative joint disease characterized by the breakdown of cartilage. The scope includes but is not limited to pharmaceuticals like NSAIDs, corticosteroids, and analgesics, biologics, and emerging therapies such as gene therapy and stem cell treatment. The necessity for these therapeutics arises from the growing prevalence of osteoarthritis worldwide, driven by an aging population, increased obesity rates, and lifestyle changes. These therapeutics find application in reducing pain, inflammation, and improving joint function, primarily targeting affected individuals for use at clinics, hospitals, and home healthcare settings. Market growth is influenced by technological advancements, increasing R&D investments, and a rising awareness of early rehabilitation. Furthermore, the development of combination therapies and minimally invasive procedures present significant opportunities. Companies can capitalize by investing in innovative technologies and expanding their product portfolios through strategic partnerships and acquisitions. However, high treatment costs, stringent regulatory requirements, and potential side effects present limitations to market expansion. Innovation and research should focus on developing cost-effective, patient-friendly, and targeted treatment options with reduced side effects. Leveraging AI and machine learning for drug discovery and developing personalized medicine tailored to individual patient profiles could offer competitive advantages. The osteoarthritis therapeutics market is dynamic, characterized by rapid advancements and a competitive landscape necessitating constant adaptation. Companies investing in advanced research to understand the disease mechanisms and improve delivery systems will likely thrive. While promising, the market requires navigating regulatory challenges and ensuring affordability to reach a broader patient base, underscoring the need for collaboration with government bodies and healthcare institutions to facilitate widespread access and education on osteoarthritis management.

KEY MARKET STATISTICS
Base Year [2023] USD 7.90 billion
Estimated Year [2024] USD 8.69 billion
Forecast Year [2030] USD 15.78 billion
CAGR (%) 10.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Osteoarthritis Therapeutics Market

The Osteoarthritis Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of osteoarthritis across the globe
    • Potential demand for minimally invasive surgical procedures
    • Growing geriatric population coupled with increasing sports injury worldwide
  • Market Restraints
    • Concern associated with adverse effects of NSAID
  • Market Opportunities
    • Emerging pharmaceuticals therapies for osteoarthritis
    • Ongoing research and development in the osteoarthritis field
    • Increasing governments supports towards the osteoarthritis treatment
    • Rising healthcare expenditure per capita income in the emerging economies
  • Market Challenges
    • Rapid adoption of non-drug pain management therapies

Porter's Five Forces: A Strategic Tool for Navigating the Osteoarthritis Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Osteoarthritis Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Osteoarthritis Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Osteoarthritis Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Osteoarthritis Therapeutics Market

A detailed market share analysis in the Osteoarthritis Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Osteoarthritis Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Osteoarthritis Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Osteoarthritis Therapeutics Market

A strategic analysis of the Osteoarthritis Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Osteoarthritis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Almatica Pharma LLC, Anika Therapeutics, Inc., Assertio Therapeutics, Inc., Atnahs Pharma UK Limited, Bayer AG, Bioventus, Eli Lilly and Company, Ferring B.V., Fidia Farmaceutici s.p.a., Flexion Therapeutics, Inc., GlaxoSmithKline PLC, Hanmi Pharm. Co., Ltd., Horizon Therapeutics PLC, and Kitov Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Osteoarthritis Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Anatomy, market is studied across Hand Osteoarthritis, Hip Osteoarthritis, Knee Osteoarthritis, and Small Joint Osteoarthritis.
  • Based on Drug Type, market is studied across Analgesics, Corticosteroids, Nonsteroidal Anti-inflammatory Drugs, and Viscosupplementation Agents. The Analgesics is further studied across Acetaminophen and Duloxetine. The Nonsteroidal Anti-inflammatory Drugs is further studied across Aspirin, Diclofenac, Ibuprofen, and Naproxen.
  • Based on Route of Administration, market is studied across Oral Route, Parenteral Route, and Topical Route.
  • Based on Purchasing Pattern, market is studied across Over-the-Counter Drugs and Prescription Drugs.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of osteoarthritis across the globe
      • 5.1.1.2. Potential demand for minimally invasive surgical procedures
      • 5.1.1.3. Growing geriatric population coupled with increasing sports injury worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. Concern associated with adverse effects of NSAID
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging pharmaceuticals therapies for osteoarthritis
      • 5.1.3.2. Ongoing research and development in the osteoarthritis field
      • 5.1.3.3. Increasing governments supports towards the osteoarthritis treatment
      • 5.1.3.4. Rising healthcare expenditure per capita income in the emerging economies
    • 5.1.4. Challenges
      • 5.1.4.1. Rapid adoption of non-drug pain management therapies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Osteoarthritis Therapeutics Market, by Anatomy

  • 6.1. Introduction
  • 6.2. Hand Osteoarthritis
  • 6.3. Hip Osteoarthritis
  • 6.4. Knee Osteoarthritis
  • 6.5. Small Joint Osteoarthritis

7. Osteoarthritis Therapeutics Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Analgesics
    • 7.2.1. Acetaminophen
    • 7.2.2. Duloxetine
  • 7.3. Corticosteroids
  • 7.4. Nonsteroidal Anti-inflammatory Drugs
    • 7.4.1. Aspirin
    • 7.4.2. Diclofenac
    • 7.4.3. Ibuprofen
    • 7.4.4. Naproxen
  • 7.5. Viscosupplementation Agents

8. Osteoarthritis Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral Route
  • 8.3. Parenteral Route
  • 8.4. Topical Route

9. Osteoarthritis Therapeutics Market, by Purchasing Pattern

  • 9.1. Introduction
  • 9.2. Over-the-Counter Drugs
  • 9.3. Prescription Drugs

10. Osteoarthritis Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Osteoarthritis Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Osteoarthritis Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Osteoarthritis Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Almatica Pharma LLC
  • 3. Anika Therapeutics, Inc.
  • 4. Assertio Therapeutics, Inc.
  • 5. Atnahs Pharma UK Limited
  • 6. Bayer AG
  • 7. Bioventus
  • 8. Eli Lilly and Company
  • 9. Ferring B.V.
  • 10. Fidia Farmaceutici s.p.a.
  • 11. Flexion Therapeutics, Inc.
  • 12. GlaxoSmithKline PLC
  • 13. Hanmi Pharm. Co., Ltd.
  • 14. Horizon Therapeutics PLC
  • 15. Kitov Pharmaceuticals Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦